OBJECTIVE: This post hoc analysis assessed the impact of repeated incobotulinumtoxinA injections on muscle tone, disability, and caregiver burden in adults with upper-limb post-stroke spasticity. DESIGN: Data from the double-blind, placebo-controlled main period and three open-label extension cycles of two Phase 3, randomized, multicentre trials were pooled. METHODS: Subjects received incobotulinumtoxinA 400 Units at 12-week intervals (±3 days) (study 3001, NCT01392300) or ≤ 400 Units at ≥12-week intervals based on clinical need (study 0410, NCT00432666). Ashworth Scale (AS) arm sumscore (sum of elbow, wrist, finger and thumb flexor, and forearm pronator AS scores), Disability Assessment Scale (DAS), and Carer Burden Scale (CBS) scores were assessed. RESULTS: Among 465 subjects, from study baseline to 4 weeks post-injection, mean (standard deviation) AS arm sumscore improved continuously: main period, -3.23 (2.55) (placebo, -1.49 (2.09)); extension cycles 1, 2, and 3, -4.38 (2.85), -4.87 (3.05), and -5.03 (3.02), respectively. DAS principal target domain responder rate increased from 47.4% in the main period (placebo 27.2%) to 66.6% in extension cycle 3. Significant improvements in CBS scores 4 weeks post-injection accompanied improved functional disability in all cycles. CONCLUSION: IncobotulinumtoxinA conferred sustained improvements in muscle tone, disability, and caregiver burden in subjects with upper-limb post-stroke spasticity.

Faculty of Medicine and Dentistry and University Hospital Palacký University Olomouc Olomouc Czech Republic E mail

See more in PubMed

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390: 1211–1259. PubMed PMC

Lundström E, Smits A, Terént A, Borg J. Time-course and determinants of spasticity during the first six months following first-ever stroke. J Rehabil Med 2010; 42: 296–301. PubMed

Lundström E, Terént A, Borg J. Prevalence of disabling spasticity 1 year after first-ever stroke. Eur J Neurol 2008; 15: 533–539. PubMed

Urban PP, Wolf T, Uebele M, Marx JJ, Vogt T, Stoeter P, et al. . Occurrence and clinical predictors of spasticity after ischemic stroke. Stroke 2010; 41: 2016–2020. PubMed

Wissel J, Manack A, Brainin M. Toward an epidemiology of poststroke spasticity. Neurology 2013; 80: S13–S19. PubMed

Doan QV, Brashear A, Gillard PJ, Varon SF, Vandenburgh AM, Turkel CC, et al. . Relationship between disability and health-related quality of life and caregiver burden in patients with upper limb poststroke spasticity. PM&R 2012; 4: 4–10. PubMed

Sturm JW, Donnan GA, Dewey HM, Macdonell RA, Gilligan AK, Srikanth V, et al. . Quality of life after stroke: the North East Melbourne Stroke Incidence Study (NEMESIS). Stroke 2004; 35: 2340–2345. PubMed

Bakheit AM, Pittock S, Moore AP, Wurker M, Otto S, Erbguth F, et al. . A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001; 8: 559–565. PubMed

Barnes M, Schnitzler A, Medeiros L, Aguilar M, Lehnert-Batar A, Minnasch P. Efficacy and safety of NT 201 for upper limb spasticity of various etiologies – a randomized parallelgroup study. Acta Neurol Scand 2010; 122: 295–302. PubMed

Brashear A, Gordon MF, Elovic E, Kassicieh VD, Marciniak C, Do M, et al. . Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 347: 395–400. PubMed

Gracies JM, Brashear A, Jech R, McAllister P, Banach M, Valkovic P, et al. . Safety and efficacy of abobotulinumtoxinA for hemiparesis in adults with upper limb spasticity after stroke or traumatic brain injury: a double-blind randomised controlled trial. Lancet Neurol 2015; 14: 992–1001. PubMed

Kaji R, Osako Y, Suyama K, Maeda T, Uechi Y, Iwasaki M, et al. . Botulinum toxin type A in post-stroke upper limb spasticity. Curr Med Res Opin 2010; 26: 1983–1992. PubMed

Wissel J, Bensmail D, Ferreira JJ, Molteni F, Satkunam L, Moraleda S, et al. . Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: the TOWER study. Neurology 2017; 88: 1321–1328. PubMed PMC

Ward AB, Wissel J, Borg J, Ertzgaard P, Herrmann C, Kulkarni J, et al. . Functional goal achievement in post-stroke spasticity patients: the BOTOX® Economic Spasticity Trial (BEST). J Rehabil Med 2014; 46: 504–513. PubMed

Merz Pharmaceuticals LLC . Highlights of prescribing information – Xeomin®. 2020. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125360s078lbl.pdf.

Merz Pharma UK Ltd . Xeomin® (50/100/200) Summary of Product Characteristics. 2020. Available from: https://www.medicines.org.uk/emc/product/2162/smpc.

Elovic EP, Munin MC, Kaňovský P, Hanschmann A, Hiersemenzel R, Marciniak C. Randomized, placebo-controlled trial of incobotulinumtoxinA for upper-limb post-stroke spasticity. Muscle Nerve 2016; 53: 415–421. PubMed PMC

Kaňovský P, Slawek J, Denes Z, Platz T, Sassin I, Comes G, et al. . Efficacy and safety of botulinum neurotoxin NT 201 in poststroke upper limb spasticity. Clin Neuropharmacol 2009; 32: 259–265. PubMed

Kaňovský P, Slawek J, Denes Z, Platz T, Comes G, Grafe S, et al. . Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med 2011; 43: 486–492. PubMed

Marciniak C, Munin MC, Brashear A, Rubin BS, Patel AT, Slawek J, et al. . IncobotulinumtoxinA efficacy and safety in adults with upper-limb spasticity following stroke: results from the open-label extension period of a phase 3 study. Adv Ther 2019; 36: 187–199. PubMed PMC

Marciniak C, Munin MC, Brashear A, Rubin BS, Patel AT, Slawek J, et al. . Efficacy of incobotulinumtoxinA in upperlimb spasticity following stroke: results from the open-label extension period of PURE. Toxicon 2018; 156: S73–S74. PubMed PMC

Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540–542. PubMed

Platz T, Vuadens P, Eickhof C, Arnold P, Van Kaick S, Heise K. REPAS, a summary rating scale for resistance to passive movement: item selection, reliability and validity. Disabil Rehabil 2008; 30: 44–53. PubMed

Brashear A, Zafonte R, Corcoran M, Galvez-Jimenez N, Gracies JM, Gordon MF, et al. . Inter- and intrarater reliability of the Ashworth Scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002; 83: 1349–1354. PubMed

Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000; 69: 217–221. PubMed PMC

Turner-Stokes L, Fhedoroff K, Jacinto J, Maisonobe P. Results from the Upper Limb International Spasticity Study-II (ULIS-II): a large, international, prospective cohort study investigating practice and goal attainment following treatment with botulinum toxin A in real-life clinical management. BMJ Open 2013; 3: pii: e002771. PubMed PMC

Bakheit AM, Thilmann AF, Ward AB, Poewe W, Wissel J, Muller J, et al. . A randomized, double-blind, placebocontrolled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke. Stroke 2000; 31: 2402–2406. PubMed

Childers MK, Brashear A, Jozefczyk P, Reding M, Alexander D, Good D, et al. . Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004; 85: 1063–1069. PubMed

Bakheit AMO, Fedorova NV, Skoromets AA, Timerbaeva SL, Bhakta BB, Coxon L. The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004; 75: 1558–1561. PubMed PMC

Seo HG, Paik NJ, Lee SU, Oh BM, Chun MH, Kwon BS, et al. . Neuronox versus BOTOX in the treatment of post-stroke upper limb spasticity: a multicenter randomized controlled trial. PloS One 2015; 10: e0128633. PubMed PMC

Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, et al. . Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med 2015; 163: 461–464. PubMed